Ophthalmology Therapeutics: Does current pipeline innovation hold the potential to affect the future ophthalmology market?

This Frontier Pharma: Ophthalmology Therapeutics assesses first-in-class innovation in the ophthalmology pipeline, highlighting key trends in the distribution of these products.

Pune, India - March 14, 2018 /MarketersMedia/ —

The pipeline is varied in terms of molecular targets and molecule types. Products acting on the immune system and neurotransmitter signaling are the most prevalent, but no single target dominates by any clear margin. There are a total of 194 first-in class pipeline products in development for ophthalmologic indications 38% of the 512 pipeline products for which there is a disclosed molecular target. Encompassing gene therapies, slowing of the visual cycle and antisense therapies, the pipeline appears robust and has huge potential to strengthen treatment options for ophthalmological disorders.

Access Report Details at: https://www.themarketreports.com/report/frontier-pharma-ophthalmology-therapeutics-gene-therapies-and-first-in-class-targets-offer-novel-treatments-for-substantial-unmet-needs-in-a-pipeline-dominated-by-angiogenic-and-immune-signaling-drugs

Reasons To Buy
• Understand the current clinical and commercial landscape. This includes a comprehensive study of disease pathogenesis, diagnosis and prognosis, and the treatment options available.
• Visualize the composition of the ophthalmological disorders market in terms of dominant molecule types and targets, and understand the current unmet needs and how they can be addressed. This knowledge allows a competitive understanding of gaps in the market.
• Analyze the ophthalmological disorders pipeline and stratify by stage of development, molecule type and molecular target. There are strong signs in the pipeline that the industry is seeking novel approaches to treating ophthalmological disorders to overcome the overwhelming level of unmet need.
• Assess the therapeutic potential of first-in-class targets. Using a proprietary matrix, first-in-class products have been assessed and ranked according to clinical potential. Promising early-stage targets have been reviewed in greater detail.
• Identify commercial opportunities in the ophthalmological disorders deals landscape by analyzing trends in licensing and co-development deals, and a curated list of ophthalmological disorder therapies that have not yet been involved in deals, and may offer potential investment opportunities.

Get this report at: https://www.themarketreports.com/report/buy-now/935550

In the past the ophthalmological disorders therapy area has suffered from a lack of full understanding of the pathophysiology and underlying mechanisms of the diseases. However, as this knowledge has improved vastly in recent years, potential targets have been identified for treatment. As well as the main disorders previously mentioned, there is also interest in developing treatments for indications such as allergic conjunctivitis and retinitis pigmentosa. The approval of a gene therapy for retinitis pigmentosa is indicative of this progress, and represents the first gene therapy approved for an inherited condition by the FDA.

Inquire for more details at: https://www.themarketreports.com/report/ask-your-query/935550

Contact Info:
Name: Shirish Gupta
Email: sales@themarketreports.com
Organization: The Market Reports
Address: SF-29, Sacred World, Wanawadi
Phone: 16314071315

Source URL: https://marketersmedia.com/ophthalmology-therapeutics-does-current-pipeline-innovation-hold-the-potential-to-affect-the-future-ophthalmology-market/314326

For more information, please visit https://www.themarketreports.com/report/frontier-pharma-ophthalmology-therapeutics-gene-therapies-and-first-in-class-targets-offer-novel-treatments-for-substantial-unmet-needs-in-a-pipeline-dominated-by-angiogenic-and-immune-signaling-drugs%20%20

Source: MarketersMedia

Release ID: 314326

Latest News

'No crazy stuff in it': Mexico budget keeps expectations in check

Dec 16, 2018

By Dave GrahamMEXICO CITY (Reuters) - Mexico's new leftist government presented a first budget aimed at calming nervous markets while honoring pledges to increase welfare spending, saying it would run a bigger surplus next year once interest payments on debt were excluded.Finance Minister Carlos Urzua presented the budget on Saturday evening, setting out plans to find more money for both the elderly and unemployed youngsters by slimming down several government ministries and through forecasts of higher tax revenues.The budget is a major test of President Andres Manuel Lopez Obrador's economic credibility, which was shaken when he said on Oct. 29...

2018: The year volatility came home to roost

Dec 16, 2018

By Saqib Iqbal AhmedNEW YORK (Reuters) - U.S. stocks are down only slightly for 2018, but that masks a volatile year for investors.Trade-related tensions between the United States and China, weakness in the tech sector, concerns about slowing global growth and jitters about the Federal Reserve marching toward higher interest rates have kept investors on their toes.Daily gyrations for the S&P 500 Index spiked sharply this year and remain near a one-year high.One-month historical volatility - a measure of how much stocks have swung on a daily basis over the course of a month - has risen to 21 percent,...

Executive's arrest, security worries stymie Huawei's reach

Dec 16, 2018

BEIJING — While a Huawei executive faces possible U.S. charges over trade with Iran, the Chinese tech giant's ambition to be a leader in next-generation telecoms is colliding with security worries abroad. Australia and New Zealand have barred Huawei Technologies Ltd. as a supplier for fifth-generation networks. They joined the United States and Taiwan, which limit use of technology from the biggest global supplier of network switching gear. This week, Japan's cybersecurity agency said Huawei and other vendors deemed risky will be off-limits for government purchases. None has released evidence of wrongdoing by Huawei, which denies it is a risk...

Nations agree on global climate pact rules, but they are seen as weak

Dec 16, 2018

By Nina Chestney, Bate Felix and Agnieszka BarteczkoKATOWICE, Poland (Reuters) - Nearly 200 countries overcame political divisions late on Saturday to agree on rules for implementing a landmark global climate deal, but critics say it is not ambitious enough to prevent the dangerous effects of global warming.After two weeks of talks in the Polish city of Katowice, nations finally reached consensus on a more detailed framework for the 2015 Paris Agreement, which aims to limit a rise in average world temperatures to "well below" 2 degrees Celsius (3.6 degrees Fahrenheit) above pre-industrial levels."It is not easy to find agreement on...

China's Xi to address key reform anniversary on Tuesday: Xinhua

Dec 16, 2018

BEIJING (Reuters) - President Xi Jinping will make a major speech on Tuesday to mark the 40th anniversary of China's reform and opening up, state news agency Xinhua reported.Xi will speak at a conference to be held at the Great Hall of the People from 10 a.m. (0200 GMT) on Tuesday, Xinhua said on Sunday. The report was in line with what diplomatic sources had previously told Reuters.Former leader Deng Xiaoping initiated China's historic reform and opening up in 1978, followed by a series of capitalist experiments that lifted much of China out of poverty and turned it into an...

Search

Obserworld delivers the most accurate and up-to-date world news for the global audience with a thorough research and in-depth interviews. Discover the world through Obserworld.

Contact us: sales[at]obserworld.com